<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365480</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-00173</org_study_id>
    <secondary_id>NCI-2015-00173</secondary_id>
    <secondary_id>N01-CN-2012-00035</secondary_id>
    <secondary_id>NCI2014-03-01</secondary_id>
    <secondary_id>NWU2014-03-01</secondary_id>
    <secondary_id>N01CN00035</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT02365480</nct_id>
  </id_info>
  <brief_title>Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission</brief_title>
  <official_title>Phase I Trial of Berberine in Subjects With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, pilot phase I trial studies the side effects of berberine chloride in&#xD;
      treating patients with ulcerative colitis and who are in remission (a decrease in or&#xD;
      disappearance of signs and symptoms of cancer) to reduce the risk of colorectal cancer.&#xD;
      Patients with ulcerative colitis are at increased risk for colorectal cancer. Chemoprevention&#xD;
      is the use of drugs, such as berberine chloride, to keep a disease/condition from forming or&#xD;
      coming back. The use of berberine chloride may keep colorectal cancer from forming in&#xD;
      patients with ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety of berberine (berberine chloride) administered to participants&#xD;
      with ulcerative colitis (UC) in clinical remission while receiving maintenance therapy with&#xD;
      mesalamine.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the molecular efficacy of berberine by examining the following biomarkers:&#xD;
&#xD;
        -  Plasma-based measures of inflammation, including the blood C-reaction protein (CRP)&#xD;
           level, erythrocyte sedimentation rate (ESR), and cytokines such as TNFa, IL-4, IL-6,&#xD;
           IL-8 and IL-10 measured by enzyme-linked immunosorbent assay (ELISA).&#xD;
&#xD;
        -  Tissue-based measures of inflammation, including TNFα, COX-2, and NF-kappa (κ)B by&#xD;
           immunohistochemistry (IHC), and anti-cancer action, including antigen Ki-67 (Ki67) and&#xD;
           activated caspase-3 by IHC, and deoxyribonucleic acid (DNA) methylation on SFRP1,&#xD;
           TCERG1L FBN2, TFPI2 using the methylation-specific polymerase chain reaction (qMSP)&#xD;
           strategy.&#xD;
&#xD;
      II. Clinical efficacy: UC related symptoms will be measured using the Ulcerative Colitis&#xD;
      Disease Activity Index (i.e. the Mayo score) (UCDAI).&#xD;
&#xD;
      III. Histological analysis for inflammation: severity of histologic inflammation will be&#xD;
      evaluated using the Geboes grading system.&#xD;
&#xD;
      IV. Determine plasma concentration of berberine.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive berberine chloride orally (PO) thrice daily (TID) for 90 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Participants receive placebo PO TID for 90 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are follow-up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2016</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0</measure>
    <time_frame>Baseline up to 30 days post-treatment (up to 120 days total)</time_frame>
    <description>Relevant counts and rates will be evaluated and reported by standard clinical tests. Symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants will be observed and recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0</measure>
    <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
    <description>Evaluated by standard clinical tests. Symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants will be observed and recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy of Berberine Chloride Measured Using the UCDAI Score</measure>
    <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
    <description>UC related symptoms measured using the Ulcerative Colitis Disease Activity Index [UCDAI]. Score results may range from 0 to 12. 0 indicates normal disease and a higher score up to 12 indicates severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Markers of Inflammation Via ELISA</measure>
    <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
    <description>TNF-α, a cytokine plasma-based measure of inflammation, measured by enzyme linked immunosorbent assay (ELISA). A numeric value in pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Colorectal Tissue Biomarkers Expression by IHC</measure>
    <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
    <description>Ki-67, a tissue based measure of inflammation, staining was graded and scored on a scale. The higher the score, the greater the expression of Ki-67:&#xD;
0 = no cells stained&#xD;
= 1/3 of cells stained&#xD;
= 1/2 of cells stained&#xD;
= ≥ 2/3 of cells stained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Berberine Chloride Concentration Measurement Using High-performance Liquid Chromatography/Mass Spectrometry</measure>
    <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
    <description>Change in blood berberine chloride concentration measurement measured using high-performance liquid chromatography/mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Histologic Inflammation</measure>
    <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
    <description>Histologic sections will be stained with hematoxylin and eosin and the severity of histologic inflammation will be evaluated using the Geboes scoring system. The Geboes score is taken as the highest category of change among the following: 0.0-0.3, structural change only; 1.0-1.3, chronic inflammation; 2.0-2.3, lamina propria neutrophils; 3.0-3.3, neutrophils in epithelium; 4.0-4.3, crypt destruction; and 5.0-5.4, erosions or ulcers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Arm I (berberine chloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine Chloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (berberine chloride)</arm_group_label>
    <other_name>Berberine Chloride Dihydrate</other_name>
    <other_name>Berberine Hydrochloride</other_name>
    <other_name>Berberinum Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (berberine chloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ulcerative colitis in clinical remission (UCDAI) =&lt; 1 for at least 3&#xD;
             months, regardless of how long ago they were diagnosed for UC&#xD;
&#xD;
          -  Receiving maintenance therapy with mesalamine for at least 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 70%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/microliter&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/microliter&#xD;
&#xD;
          -  Platelets &gt;= 100,000/microliter&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits; higher values (=&lt; 3 x&#xD;
             institutional upper limit of normal [ULN]) are acceptable in participants with: 1.&#xD;
             known or suspected cholangitis associated with Crohn's disease, or 2, known or&#xD;
             suspected inborn errors of metabolism that lead to increased bilirubin&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOP])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 1.5 x institutional ULN&#xD;
&#xD;
          -  Creatinine within normal institutional limits&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation; should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her study physician&#xD;
             immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have had any immunomodulatory treatment in the past 3 months will be&#xD;
             excluded&#xD;
&#xD;
          -  Participants who have taken any medicines that are inducers, inhibitors or substrates&#xD;
             of select cytochrome (CYP) isozymes within the past 3 months will be excluded;&#xD;
             participants who have consumed either grapefruit juice or Seville orange juice in the&#xD;
             past 7 days will be excluded&#xD;
&#xD;
          -  Participants with dysplasia-associated mass or lesion (DALM) due to longstanding&#xD;
             idiopathic inflammatory bowel disease will be excluded&#xD;
&#xD;
          -  Participants who are currently receiving any other investigational agents or have&#xD;
             received investigational agents within the past 3 months will be excluded&#xD;
&#xD;
          -  Participants with a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to berberine will be excluded&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that in the opinion of&#xD;
             investigators would jeopardize patient safety of data integrity are excluded;&#xD;
             individuals who are human immunodeficiency virus (HIV) positive will not necessarily&#xD;
             be excluded, will be considered on a case-by-case basis, but will be required to meet&#xD;
             criteria related to patient safety and data integrity, as assessed by investigators&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with berberine; women are considered to be of child-bearing&#xD;
             potential if they are not surgically sterile or under the age 65 and have menstruated&#xD;
             within the last two years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaichun Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <results_first_submitted>December 9, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2021</results_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02365480/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial opened to accrual 06/16/2016 and closed to accrual 10/18/2017. All participants were recruited at Xijing Hospital, Xi'an, China.</recruitment_details>
      <pre_assignment_details>Twenty participants were screened and eighteen were randomized and began study intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Berberine Chloride)</title>
          <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo)</title>
          <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Berberine Chloride)</title>
          <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo)</title>
          <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kilogram per square meter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" lower_limit="19.9" upper_limit="24.4"/>
                    <measurement group_id="B2" value="22.8" lower_limit="20.3" upper_limit="25.1"/>
                    <measurement group_id="B3" value="23.5" lower_limit="19.7" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0</title>
        <description>Relevant counts and rates will be evaluated and reported by standard clinical tests. Symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants will be observed and recorded.</description>
        <time_frame>Baseline up to 30 days post-treatment (up to 120 days total)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0</title>
          <description>Relevant counts and rates will be evaluated and reported by standard clinical tests. Symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants will be observed and recorded.</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0</title>
        <description>Evaluated by standard clinical tests. Symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants will be observed and recorded.</description>
        <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0</title>
          <description>Evaluated by standard clinical tests. Symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants will be observed and recorded.</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Efficacy of Berberine Chloride Measured Using the UCDAI Score</title>
        <description>UC related symptoms measured using the Ulcerative Colitis Disease Activity Index [UCDAI]. Score results may range from 0 to 12. 0 indicates normal disease and a higher score up to 12 indicates severe disease.</description>
        <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Efficacy of Berberine Chloride Measured Using the UCDAI Score</title>
          <description>UC related symptoms measured using the Ulcerative Colitis Disease Activity Index [UCDAI]. Score results may range from 0 to 12. 0 indicates normal disease and a higher score up to 12 indicates severe disease.</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.37"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (end of intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>36.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Markers of Inflammation Via ELISA</title>
        <description>TNF-α, a cytokine plasma-based measure of inflammation, measured by enzyme linked immunosorbent assay (ELISA). A numeric value in pg/mL.</description>
        <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Markers of Inflammation Via ELISA</title>
          <description>TNF-α, a cytokine plasma-based measure of inflammation, measured by enzyme linked immunosorbent assay (ELISA). A numeric value in pg/mL.</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.47" spread="22.47"/>
                    <measurement group_id="O2" value="58.68" spread="22.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (end of intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.06" spread="19.20"/>
                    <measurement group_id="O2" value="54.68" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Colorectal Tissue Biomarkers Expression by IHC</title>
        <description>Ki-67, a tissue based measure of inflammation, staining was graded and scored on a scale. The higher the score, the greater the expression of Ki-67:&#xD;
0 = no cells stained&#xD;
= 1/3 of cells stained&#xD;
= 1/2 of cells stained&#xD;
= ≥ 2/3 of cells stained</description>
        <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Colorectal Tissue Biomarkers Expression by IHC</title>
          <description>Ki-67, a tissue based measure of inflammation, staining was graded and scored on a scale. The higher the score, the greater the expression of Ki-67:&#xD;
0 = no cells stained&#xD;
= 1/3 of cells stained&#xD;
= 1/2 of cells stained&#xD;
= ≥ 2/3 of cells stained</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.90"/>
                    <measurement group_id="O2" value="2.25" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (end of intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.47"/>
                    <measurement group_id="O2" value="1.5" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Berberine Chloride Concentration Measurement Using High-performance Liquid Chromatography/Mass Spectrometry</title>
        <description>Change in blood berberine chloride concentration measurement measured using high-performance liquid chromatography/mass spectrometry.</description>
        <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Berberine Chloride Concentration Measurement Using High-performance Liquid Chromatography/Mass Spectrometry</title>
          <description>Change in blood berberine chloride concentration measurement measured using high-performance liquid chromatography/mass spectrometry.</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.21"/>
                    <measurement group_id="O2" value="0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (end of intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="1.28"/>
                    <measurement group_id="O2" value="0.18" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Histologic Inflammation</title>
        <description>Histologic sections will be stained with hematoxylin and eosin and the severity of histologic inflammation will be evaluated using the Geboes scoring system. The Geboes score is taken as the highest category of change among the following: 0.0-0.3, structural change only; 1.0-1.3, chronic inflammation; 2.0-2.3, lamina propria neutrophils; 3.0-3.3, neutrophils in epithelium; 4.0-4.3, crypt destruction; and 5.0-5.4, erosions or ulcers.</description>
        <time_frame>Baseline to Day 90 (end of intervention)</time_frame>
        <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Berberine Chloride)</title>
            <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Histologic Inflammation</title>
          <description>Histologic sections will be stained with hematoxylin and eosin and the severity of histologic inflammation will be evaluated using the Geboes scoring system. The Geboes score is taken as the highest category of change among the following: 0.0-0.3, structural change only; 1.0-1.3, chronic inflammation; 2.0-2.3, lamina propria neutrophils; 3.0-3.3, neutrophils in epithelium; 4.0-4.3, crypt destruction; and 5.0-5.4, erosions or ulcers.</description>
          <population>Participants with ulcerative colitis in clinical remission and maintained by Mesalamine.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="1.41"/>
                    <measurement group_id="O2" value="4.68" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 (end of intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="1.66"/>
                    <measurement group_id="O2" value="4.45" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 days after randomization</time_frame>
      <desc>Adverse events deemed possibly, probably, or definitely related to the study intervention by study physician are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Berberine Chloride)</title>
          <description>Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Berberine Chloride: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo)</title>
          <description>Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Seema A. Khan, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-4236</phone>
      <email>s-khan2@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

